SCHEMBL3496499

SCHEMBL3496499

CC(=O)Nc1ccc(Nc2ncc(F)c(NC3CC(C)(C)N(C)C(C)(C)C3)n2)cc1C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 2/20 0.49
FLT3 P36888 9/20 0.49
KIT P10721 8/20 0.49
CHEK1 O14757 8/20 0.46
ULK1 O75385 4/20 0.46
CDK2 P24941 3/20 0.46
PTK2 Q05397 3/20 0.46
PLK4 O00444 2/20 0.46
AURKA O14965 2/20 0.46
PRKD3 O94806 2/20 0.46
MAP4K4 O95819 2/20 0.46
PAK4 O96013 2/20 0.46
ABL1 P00519 2/20 0.46
NTRK1 P04629 2/20 0.46
INSR P06213 2/20 0.46
FES P07332 2/20 0.46
RET P07949 2/20 0.46
IGF1R P08069 2/20 0.46
MET P08581 2/20 0.46
FGFR1 P11362 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3494216 0.87 PRKCQ (0.44) PRKCQFLT3KITCHEK1ULK1
SCHEMBL3497272 0.87 PRKCQ (0.55) PRKCQFLT3KITCHEK1ULK1
SCHEMBL3496348 0.84 PRKCQ (0.53) PRKCQFLT3KITCHEK1ULK1
SCHEMBL3496768 0.84 FLT3 (0.48) PRKCQFLT3KITCHEK1ULK1
SCHEMBL1740791 0.83 CDK2 (0.51) PRKCQFLT3KITCHEK1CDK2
SCHEMBL3494060 0.83 PRKCQ (0.57) PRKCQFLT3KITULK1PTK2
SCHEMBL3494263 0.83 PRKCQ (0.49) PRKCQFLT3KITCHEK1CDK2
SCHEMBL3495333 0.83 PRKCQ (0.53) PRKCQFLT3KITCHEK1ULK1
SCHEMBL3497119 0.82 SYK (0.53) PRKCQFLT3KITCHEK1CDK2
SCHEMBL3495812 0.82 PRKCQ (0.51) PRKCQCHEK1ULK1SYKCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US claimed
EP-2183225-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2010-05-12 EP claimed
WO-2009012421-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2009-01-22 WO claimed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed
EP-2183225-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2010-05-12 EP disclosed
WO-2009012421-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ PRKCQ 3/4885FLT3 172/4885KIT 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.